Diabetic Gastroparesis - Pipeline Review, H2 2016

Published: Aug, 2016 | Pages: 63 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Diabetic Gastroparesis - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Diabetic Gastroparesis - Pipeline Review, H2 2016', provides an overview of the Diabetic Gastroparesis pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Diabetic Gastroparesis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Gastroparesis and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Diabetic Gastroparesis
- The report reviews pipeline therapeutics for Diabetic Gastroparesis by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Diabetic Gastroparesis therapeutics and enlists all their major and minor projects
- The report assesses Diabetic Gastroparesis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Diabetic Gastroparesis

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Diabetic Gastroparesis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Diabetic Gastroparesis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table Of Content

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Diabetic Gastroparesis Overview 7
Therapeutics Development 8
Pipeline Products for Diabetic Gastroparesis - Overview 8
Pipeline Products for Diabetic Gastroparesis - Comparative Analysis 9
Diabetic Gastroparesis - Therapeutics under Development by Companies 10
Diabetic Gastroparesis - Therapeutics under Investigation by Universities/Institutes 11
Diabetic Gastroparesis - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Diabetic Gastroparesis - Products under Development by Companies 15
Diabetic Gastroparesis - Products under Investigation by Universities/Institutes 16
Diabetic Gastroparesis - Companies Involved in Therapeutics Development 17
Cempra Inc 17
Evoke Pharma, Inc. 18
GlaxoSmithKline Plc 19
Motus Therapeutics Inc 20
Shire Plc 21
Theravance Biopharma, Inc. 22
Diabetic Gastroparesis - Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Target 24
Assessment by Mechanism of Action 26
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 32
camicinal - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
CEM-031 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
ETX-101 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
ETX-301 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
metoclopramide hydrochloride - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
prucalopride succinate - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
relamorelin - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
Small Molecules to Activate nNOS for Diabetic Gastroparesis - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
velusetrag hydrochloride - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
Diabetic Gastroparesis - Dormant Projects 52
Diabetic Gastroparesis - Discontinued Products 53
Diabetic Gastroparesis - Product Development Milestones 54
Featured News & Press Releases 54
Jul 26, 2016: Evoke Pharma Receives Conditional FDA Acceptance of Proposed Brand Name for EVK-001 54
Jul 18, 2016: Evoke Pharma Reports Topline Results from EVK-001 Phase 3 Clinical Trial 54
Jul 07, 2016: Evoke Advances Commercial Preparations for EVK-001 with inVentiv Agreement 55
Jun 01, 2016: Evoke Completes Phase 3 Clinical Trial of EVK-001 in Women with Symptoms Associated with Diabetic Gastroparesis 55
May 24, 2016: Evoke Pharma Presents Data from Successful Thorough ECG (TQT) Study of EVK-001 at Digestive Disease Week 2016 56
May 19, 2016: Evoke Enters Exclusive Commercial Supply Agreement for Active Pharmaceutical Ingredient in EVK-001 56
May 03, 2016: Evoke Announces Timing of Phase 3 Results from its Recently Fully Enrolled Pivotal Clinical Trial of EVK-001 57
Apr 25, 2016: Evoke Successfully Completes Phase 3 Clinical Trial Enrollment of EVK-001 in Women with Symptoms Associated with Diabetic Gastroparesis 57
Apr 04, 2016: Motus Completes Enrollment of Phase 2b Clinical Trial of Relamorelin for Diabetic Gastroparesis 58
Mar 03, 2016: Evoke Accelerates New Drug Application Process by Engaging Regulatory Experts 58
Mar 01, 2016: Evoke Nears Completion of Phase 3 Clinical Trial Enrollment and Secures Extension to Credit Facility 59
Feb 17, 2016: Evoke Pharma to Present Results From Successful Thorough ECG (TQT) Study of EVK-001 at Digestive Disease Week 2016 59
Sep 28, 2015: Evoke Reaches Study Enrollment Milestone Associated With Credit Facility 60
Aug 18, 2015: Evoke Receives Favorable Response From U.S. Food and Drug Administration Regarding Pediatric Study Plan for EVK-001 60
Jun 24, 2015: Evoke Pharma Announces Publication of Clinical Data Demonstrating EVK-001 Significantly Improves Symptoms in Women With Diabetic Gastroparesis 61
Appendix 62
Methodology 62
Coverage 62
Secondary Research 62
Primary Research 62
Expert Panel Validation 62
Contact Us 62
Disclaimer 63

List Of Tables

Number of Products under Development for Diabetic Gastroparesis, H2 2016 8
Number of Products under Development for Diabetic Gastroparesis - Comparative Analysis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Number of Products under Investigation by Universities/Institutes, H2 2016 11
Comparative Analysis by Late Stage Development, H2 2016 12
Comparative Analysis by Clinical Stage Development, H2 2016 13
Comparative Analysis by Early Stage Development, H2 2016 14
Products under Development by Companies, H2 2016 15
Products under Investigation by Universities/Institutes, H2 2016 16
Diabetic Gastroparesis - Pipeline by Cempra Inc, H2 2016 17
Diabetic Gastroparesis - Pipeline by Evoke Pharma, Inc., H2 2016 18
Diabetic Gastroparesis - Pipeline by GlaxoSmithKline Plc, H2 2016 19
Diabetic Gastroparesis - Pipeline by Motus Therapeutics Inc, H2 2016 20
Diabetic Gastroparesis - Pipeline by Shire Plc, H2 2016 21
Diabetic Gastroparesis - Pipeline by Theravance Biopharma, Inc., H2 2016 22
Assessment by Monotherapy Products, H2 2016 23
Number of Products by Stage and Target, H2 2016 25
Number of Products by Stage and Mechanism of Action, H2 2016 27
Number of Products by Stage and Route of Administration, H2 2016 29
Number of Products by Stage and Molecule Type, H2 2016 31
Diabetic Gastroparesis - Dormant Projects, H2 2016 52
Diabetic Gastroparesis - Discontinued Products, H2 2016 53